Clinical Trial ProgressAPOLLO enrollment is accelerating, enhancing the robustness of data readout.
Financial PositionMRKR secured more than $13 million in non-dilutive funding in 2024 to advance its lead product MT-601.
Regulatory PotentialThere would be significant upside to the estimates if Marker Therapeutics gains FDA approval in more indications, more quickly than anticipated, or achieves faster market penetration.